StockData
Journey Medical Corp logo

Journey Medical Corp (DERM) stock

DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3033% below fair value
$3.90+0.20 (+5.41%)

Close on Nov 17, 2026Market cap $110.08MP/E –Yield –

Journey Medical operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Journey Medical's operating income for the twelve months ending Jun 30, 2026 was -$3.01M. For fiscal 2025 it was -$8.17M. The highest annual figure on record is $7.85M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.17M–
FY2024Dec 31, 2024-$13.68M–
FY2023Dec 31, 2023-$2.07M–
FY2022Dec 31, 2022-$27.52M–
FY2021Dec 31, 2021-$34.88M-544.3%
FY2020Dec 31, 2020$7.85M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$456.00K–
Q1 FY2026Mar 31, 2026-$1.49M–
Q4 FY2025Dec 31, 2025-$443.00K-119.8%
Q3 FY2025Sep 30, 2025-$1.53M–
Q2 FY2025Jun 30, 2025-$2.88M–
Q1 FY2025Mar 31, 2025-$3.32M–
Q4 FY2024Dec 31, 2024$2.23M–
Q3 FY2024Sep 30, 2024-$2.89M-116.8%
Q2 FY2024Jun 30, 2024-$2.93M–
Q1 FY2024Mar 31, 2024-$10.09M–
Q4 FY2023Dec 31, 2023-$2.10M–
Q3 FY2023Sep 30, 2023$17.25M–
Q4 FY2022Dec 31, 2022-$10.00M–
Q3 FY2022Sep 30, 2022-$9.49M–
Q2 FY2022Jun 30, 2022-$7.14M–
Q1 FY2022Mar 31, 2022-$888.00K-251.8%
Q4 FY2021Dec 31, 2021-$9.06M-349.8%
Q3 FY2021Sep 30, 2021-$12.65M-5391.2%
Q2 FY2021Jun 30, 2021-$13.76M–
Q1 FY2021Mar 31, 2021$585.00K–
Q4 FY2020Dec 31, 2020$3.63M–
Q3 FY2020Sep 30, 2020$239.00K–

More Journey Medical figures

See a number that looks wrong?